Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9P0Z9
UPID:
SOX_HUMAN
Alternative names:
L-pipecolate oxidase; L-pipecolic acid oxidase
Alternative UPACC:
Q9P0Z9; B3KNH0; Q96H28; Q9C070
Background:
Peroxisomal sarcosine oxidase, also known as L-pipecolate oxidase or L-pipecolic acid oxidase, plays a crucial role in the metabolism of sarcosine and L-pipecolic acid. This enzyme's activity is pivotal in the catabolic pathways of these substrates, indicating its essential function in cellular metabolism.
Therapeutic significance:
Understanding the role of Peroxisomal sarcosine oxidase could open doors to potential therapeutic strategies. Its involvement in key metabolic processes highlights its potential as a target for therapeutic intervention in metabolic disorders.